Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins

PROTAC targeted protein degraders: the past is prologue

(2022) Miklós Békés et al.   NATURE REVIEWS DRUG DISCOVERY

Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

(2021) Adam D. Cotton et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins

(2021) Yaxian Zhou et al.   ACS Central Science

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

(2021) Green Ahn et al.   Nature Chemical Biology

Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

(2021) Florian Kast et al.   Nature Communications

Lysosome-targeting chimaeras for degradation of extracellular proteins

(2020) Steven M. Banik et al.   NATURE

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells

(2020) Wen-Qi Cai et al.   Frontiers in Oncology

Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2

(2020) Colton J. Bracken et al.   Nature Chemical Biology

Expression Atlas update: from tissues to single cells

(2019) Irene Papatheodorou et al.   NUCLEIC ACIDS RESEARCH

Frizzled Receptors as Potential Therapeutic Targets in Human Cancers

(2018) Chui-Mian Zeng et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

(2017) Atrish Bagchi et al.   MOLECULAR CANCER THERAPEUTICS

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab

(2017) Fei Zhang et al.   Oncotarget

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance

(2016) E. Allen Sickmier et al.   PLoS One

A High Through-put Platform for Recombinant Antibodies to Folded Proteins

(2015) Michael Hornsby et al.   MOLECULAR & CELLULAR PROTEOMICS

Bispecific T-cell engagers for cancer immunotherapy

(2014) Amelia M Huehls et al.   IMMUNOLOGY AND CELL BIOLOGY

Revisiting the Role of Glycosylation in the Structure of Human IgG Fc

(2012) M. Jack Borrok et al.   ACS Chemical Biology

ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner

(2012) Huai-Xiang Hao et al.   NATURE

Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α

(2010) Curtis A Thorne et al.   Nature Chemical Biology

Therapeutic antibodies: successes, limitations and hopes for the future

(2009) Patrick Chames et al.   BRITISH JOURNAL OF PHARMACOLOGY

Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation

(2009) A. Talavera et al.   CANCER RESEARCH

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

(2009) T. P. J. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization

(2008) Judith Schmiedel et al.   CANCER CELL